Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells

Brain Research

Volumn 741, Issue 1-2, 1996, Pages 275-283

  Crain, Stanley M ^a   Shen, Ke Fei ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

funaltrexamine; vs. opioid receptors; action potential shortening vs. prolongation; dorsal root ganglion neuron; naltrindole; nor binaltorphimine

Indexed keywords

BETA ENDORPHIN; BETA FUNALTREXAMINE; ETORPHINE; GANGLIOSIDE GM1; MORPHINE; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE RECEPTOR; PERTUSSIS TOXIN; RECEPTOR SUBTYPE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; ELECTROPHYSIOLOGY; EMBRYO; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; SPINAL GANGLION; TISSUE CULTURE;

ACTION POTENTIALS; ANALGESICS, OPIOID; ANIMALS; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; ETORPHINE; G(M1) GANGLIOSIDE; GANGLIA, SPINAL; MICE; MORPHINE; NEURONS, AFFERENT; PATCH-CLAMP TECHNIQUES; PERTUSSIS TOXIN; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; VIRULENCE FACTORS, BORDETELLA;

EID: 0030602037     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00982-1     Document Type: Article

References (62)

1. [1] Bentley, K.W. and Hardy, D.G., New potent analgesics in the morphine series, Proc. Chem. Soc., (1963) 220.
2. [2] Bentley, K.W. and Hardy D.G., Novel analgesics and molecular rearrangements in the morphine-thebaine group. III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of n-allylnormorphine and -norcodeine, J. Am. Chem. Soc., 89 (1967) 3281-3292.
3. 2-adrenergic receptors, Mol. Brain Res., 28 (1995) 72-80.
4. [4] Blane, G.F. and Robbie, D.S., Trial of etorphine hydrochloride (M99 Reckitt) in carcinoma pain, preliminary report, Proc. Br. Pharmacol. Soc., 20 (1970) 252-253P.
5. [5] Blane, G.F. and Robbie, D.S., Compounds of the oripavine series. In H.W. Kosterlitz, H.O.J. Collier and J.E. Villareal (Eds.), Agonist and Antagonist Action of Narcotic Analgesic Drugs, Univ. Park Press, Baltimore, MD, 1973, pp. 120-127.
6. [6] Blane, G.F., Boura, A.L.A., Fitzgerald, A.E. and Lister, R.E., Actions of etorphine hydrochloride (M99): a potent morphine-like agent. Br. J. Pharmacol. Chemother., 30 (1967) 11-22.
7. [7] Chalazonitis, A. and Crain, S.M., Maturation of opioid sensitivity of fetal mouse dorsal-root ganglion neuron perikarya in organotypic cultures: regulation by spinal cord, Neuroscience, 17 (1986) 1181-1198.
8. [8] Chang, K.J., Hazum, E. and Cuatrecasas, P., Novel opiate binding sites selective for benzomorphan drugs (enkephalins, morphine, diprenorphine, kappa and delta receptors), Proc. Natl. Acad. Sci. USA, 78 (1981) 4141-4145.
9. [9] Crain, S.M., Neurophysiologic Studies in Tissue Culture, Raven Press, New York, 1976.
10. [10] Crain, S.M. and Shen, K.-F., Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons, Trends Pharmacol. Sci., 11 (1990) 77-81.
11. [11] Crain, S.M. and Shen, K.-F., After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside, Brain Res., 575 (1992) 13-24.
12. [12] Crain, S.M. and Shen, K.-F., After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition, J. Pharmacol. Exp. Ther., 260 (1992) 182-186.
13. [13] Crain, S.M. and Shen, K.-F., Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. In R.S. Repaka and H. Sorer (Eds.), Discovery of Novel Opioid Medications, NIDA Monograph, US Govt. Print. Office, Washington, DC, 1995, pp. 234-268.
14. [14] Crain, S.M. and Shen K.-F., Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment, Proc. Natl. Acad. Sci. USA, 92 (1995) 10540-10544.
15. [15] Crain, S.M. and Shen K.-F., Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: an in vitro model of 'protracted opioid dependence', Brain Res., 694 (1995) 103-110.
16. [16] Crain, S.M., Shen, K.-F. and Chalazonitis, A., Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures, Brain Res., 455 (1988) 99-109.
17. [17] Cruciani, R.A., Dvorkin, B., Morris, S.A., Crain, S.M. and Makman, M.H., Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells. Proc. Natl. Acad. Sci. USA, 90 (1993) 3019-3023.
18. 2-adrenergic receptors to two G-proteins with opposing effects, J. Biol. Chem., 267 (1992) 15759-15801.
19. k decreases in cultured sensory neurons, Soc. Neurosci. Abstr., 20 (1994) 750.
20. + conductance of DRG neurons and neuroblastoma × DRG neuron hybrid F11 cells, Brain Res., 696 (1995) 97-105.
21. [21] Fields, A., Gafni, M., Oron, Y. and Same, Y., Multiple effects of opiates on intracellular calcium level and on calcium uptake in three neuronal cell lines, Brain Res., 687 (1995) 94-102.
22. [22] Gross, R.A., Moises, H.C., Uhler, M.D. and Macdonald, R.L., Dynorphin A and CAMP-dependent protein kinase independently regulate neuronal calcium currents, Proc. Natl. Acad. Sci. USA, 87 (1990) 7025-7029.
23. [23] Hammonds, R.G. Jr., Nicolas, P. and Li, C.H., β-endorphin(1-27) is an antagonist of β-endorphin analgesia, Proc. Natl. Acad. Sci. USA, 81 (1984) 1389-1390.
24. [24] Horan, P.J., Mattia, A., Bilsky, E.J., Weber, S., Davis, T.P., Yamamura, H.I., Malatynska, E., Appleyard, S.M., Slaninova, J., Misicka, A., Lipkowski, A.W., Hruby, V.J. and Porreca, F., Antinociceptive profile of biphalin, a dimeric enkephalin analog, J. Pharmacol. Exp. Ther., 26 (1993) 1446-1454.
25. [25] Jasinski, D.R., Griffith, J.D. and Carr, C.B., Etorphine in man. 1. Subjective effects and suppression of morphine abstinence, Clin. Pharmacol. Ther., 17 (1975) 267-272.
26. [26] Katsumata, S., Minami, M., Nakagawa, T., Iwamura, T. and Satoh, M., Pharmacological study of dihydroetorphine in cloned μ-, δ- and κ-opioid receptors, Eur. J. Pharmacol., 291 (1995) 367-373.
27. [27] Kosterlitz, H.W. and Paterson, S.J., Characterization of opioid receptors in nervous tissue, Proc. Roy. Soc. Lond., 210 (1980) 113-121.
28. [28] Lange, D.G., Fujimoto, J.M., Fuhrman-Lane, C.L. and Wang, R.I.H., Unidirectional non-cross-tolerance to etorphine in morphine-tolerant mice and role of the blood-brain barrier, Toxicol. Appl. Pharmacol., 54 (1980) 177-186.
29. [29] Magnan, J., Paterson, S.J., Tavani, A. and Kosterlitz, H.W., The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties, Naunyn-Schmiedeberg's Arch. Pharmacol., 319 (1982) 197-205.
30. [30] Makman, M.H., Dvorkin, B. and Crain, S.M., Modulation of adenylate cyclase activity of mouse spinal cord-ganglion explants by opioids, serotonin and pertussis toxin, Brain Res., 445 (1988) 303-313.
31. [33] Mudge, A.W., Leeman, S.E. and Fischbach, G.D., Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration, Proc. Natl. Acad. Sci. USA, 16 (1979) 526-530.
32. [32] Nicholas, P. and Li, C.H., B-endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia, Proc. Natl. Acad. Sci. USA, 82 (1985) 3178-3181.
33. [33] Niwa, M., Al-Essa, L.Y., Ohta, S., Kohno, K., Nozaki, M., Tsurumi, K., Iwamura, T. and Kataoka, T., Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine, Life Sci., 56PL (1995) 395-400.
34. [34] Nock, B., Giordans, A.L., Cicero, T.J. and O'Connor, L.H., Affinity of drugs and peptides for U-69,593-sensitive and -insensitive kappa opioid binding sites: the U-69,593-insensitive sites appear to be the beta-endorphin-specific epsilon receptor, J. Pharmacol. Exp. Ther., 254 (1990) 412-419.
35. [35] Nock, B., Giordano, A.L., Moore, B.W. and Cicero, T.J., Properties of the putative epsilon opioid receptor: identification in rat, guinea pig, cow, pig and chicken brain, J. Pharmacol. Exp. Ther., 264 (1993) 349-359.
36. [36] North, R.A., Opioid receptor types and membrane ion channels, Trends Neurosci., 9 (1986) 114-117.
37. 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation, Cell, 67 (1991) 723-730.
38. [38] Portoghese, P.S., Sultana, M. and Takemori, A.E., Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur. J. Pharmacol., 146 (1988) 185-186.
39. [39] Qin, B.-Y., Research advances of dihydroetorphine: from analgesia to detoxification, New Drugs Clin. Remedies, 12 (1993) 119-123.
40. [40] Shen, K.-F. and Crain S.M., Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture, Brain Res., 491 (1989) 227-242.
41. [41] Shen, K.-F. and Crain. S.M., Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors, Brain Res., 525 (1990) 225-231.
42. [42] Shen, K.-F. and Crain, S.M., Cholera-toxin-B subunit blocks excitatory effects of opioids on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions, Brain Res., 531 (1990) 1-7.
43. [43] Shen, K.-F. and Crain, S.M., Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid dependence without tolerance, Brain Res., 597 (1992) 74-83.
44. [44] Shen, K.-F. and Crain, S.M., Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence, Brain Res., 636 (1994) 286-297.
45. [45] Shen, K.-F. and Crain, S.M., Nerve growth factor rapidly prolongs the action potential of mature sensory neurons in culture and this effect requires activation of Gs-coupled excitatory kappa opioid receptors on these cells, J. Neurosci., 14 (1994) 5570-5579.
46. [46] Shen, K.-F. and Crain, S.M., Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture, Brain Res., 701 (1995) 158-166.
47. [47] Shen, K.-F. and Crain, S.M., Ultra-low doses of naltrexone or etorphine selectively antagonize excitatory opioid receptor functions, thereby increasing morphine's antinociceptive potency and attenuating tolerance/dependence in mice, Brain Res., submitted.
48. [48] Shen, K.-F., Crain, S.M. and Ledeen, R.W., Brief treatment of sensory ganglion neurons with GM1 ganglioside enhances the efficacy of opioid excitatory effects on the action potential, Brain Res., 559 (1991) 130-138.
49. [49] Suarez-Roca, H. and Maixner, W., Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. J. Pharmacol Exp. Ther., 264 (1993) 648-653.
50. [50] Suh, H.H., Tseng, L.F. and Li, C.H., β-Endorphin-(1-27) antagonizes β-endorphin-but not morphine-, D-Pen,D-Pen-enkephalin-and U50,488H-induced analgesia in mice, Neuropharmacology, 27 (1988) 957-963.
51. [51] Takemori, A.E., Ho, B.Y., Naeseth, J.S. and Portoghese, P.S., Nor-binaltorphimine, a highly selective κ-opioid antagonist in analgesic and receptor binding assays, J. Pharmacol. Exp. Ther., 246 (1988) 255-258.
52. [52] Tao, P.L., Law, P.-Y. and Loh, H.H., Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment, J. Pharmacol. Exp. Ther., 240 (1987) 809-816.
53. [53] Tokuyama, S., Takahashi, M. and Kaneto, H., Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice, Biol. Pharm. Bull., 16 (1993) 774-777.
54. [54] Tokuyama, S., Nakamura, F., Takahashi, M. and Kaneto, H., Physical dependence produced by dihydroetorphine in mice, Biol. Pharm. Bull., 17 (1994) 1056-1059.
55. [55] Tseng, L.F. and Collins, K.A., Pretreatment with pertussis toxin blocks morphine- but not β-endorphin-induced antinociception in the mouse, Eur. J. Pharmacol., 294 (1995) 345-348.
56. [56] Uhl, G.R., Childers, S. and Pasternak, G., An opiate-receptor gene family reunion, Trends Neurophysiol., 17 (1994) 89-93.
57. [57] Wang, D.X., Liu, Y.S. and Qin, B.Y., Experimental treatment of dihydroetorphine and naloxone on morphine-dependent rats and monkeys, Chin. J. Pharmacol. Toxicol., 6 (1992) 36-40.
58. [58] Ward, S.J., Portoghese, P.S. and Takemori, A.E., Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine, J. Pharmacol. Exp. Ther., 220 (1982) 494-498.
59. [59] Werz, M.A. and Macdonald, R.L., Opioid peptides with differential affinity for mu- and delta-receptors decrease sensory neuron calcium-dependent action potentials, J. Pharmacol. Exp. Ther., 227 (1983) 394-402.
60. [60] Wu, G., Lu, Z. and Ledeen, R.W., GM1 conversion of a cloned δ opioid receptor from inhibitor to stimulator of adenyl cyclase, J. Neurochem., 64 (1995) S104.
61. + currents, J. Neurosci Res., 42 (1995) 493-503.
62. [62] Xu, J.Y., Fujimoto, J.M. and Tseng, L.F., Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse, J. Pharmacol. Exp. Ther., 263 (1992) 246-252.